Ceritinib is a targeted therapy for ALK-positive non-small cell lung cancer. It works by inhibiting ALK proteins that drive cancer cell growth. Ceritinib's clinical relevance lies in its effectiveness for treating specific lung cancers. In summary, Ceritinib is essential for managing ALK-positive lung cancer.
Ceritinib inhibits ALK tyrosine kinase activity, blocking downstream signaling pathways that promote tumor growth.
No published brands for this salt yet.